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In cell lines, the Epstein–Barr virus (EBV)-encoded protein latent membrane protein 2A (LMP2A)
protects B-cells from apoptosis by blocking B-cell receptor (BCR) signalling. However, EBV-
infected B-cells in vivo are extremely different from cell lines. This study used a murine transgenic
model in which B-cells express LMP2A and a BCR specific for hen egg lysozyme to determine
whether LMP2A protects resting and antigen-activated B-cells from apoptosis. LMP2A allows
BCR signal transduction and induces constitutive activation of NF-kB to increase Bcl-2 levels that
afford LMP2A-mediated protection from apoptosis in the absence or presence of antigen. In
contrast, low levels of NF-kB inhibitor only affected Bcl-2 and Bcl-xL levels and increased
apoptosis in LMP2A-negative B-cells after BCR cross-linking. These data suggest that LMP2A
uniquely makes resting B-cells sensitive to NF-kB inhibition and apoptosis and suggest that NF-
kB may be a novel target to eradicate latently EBV-infected B-cells.
Epstein–Barr virus (EBV) is a herpesvirus that infects over
90% of the population. After an initial infection of B-cells in
which many viral proteins are expressed, the virus transi-
tions into a latent state and expresses few viral transcripts
(Fields et al., 2007). During latency, the virus expresses
multiple gene patterns in both resting B-cells and EBV-
associated tumours (Thorley-Lawson, 2001; Thorley-
Lawson & Allday, 2008). Evidence indicates that not only
the activation state of the B-cell, but also cytokines and host
factors influence gene expression during latency (Kis et al.,
2006, 2010; Konforte & Paige, 2009; Konforte et al., 2008;
Pokrovskajaet al., 2002; Uchakin et al., 2007). Therefore, the
expression of viral transcripts may vary due to the
environment in which the latently infected B-cells reside.
Of the latency transcripts expressed by EBV, latent
membrane protein 2A (LMP2A) is consistently detected
(Babcock et al., 1998, 2000; Babcock & Thorley-Lawson,
2000; Decker et al., 1996; Hochberg et al., 2004; Qu &
Rowe, 1992; Tierney et al., 1994; Tsai et al., 2009). Previous
reports demonstrate that LMP2A protects B-cells from
apoptosis in LMP2A-expressing cell lines (Fukuda &
Longnecker, 2005; Mancao & Hammerschmidt, 2007).
One mechanism by which LMP2A performs this function
is by blocking the signalling through the B-cell receptor
(BCR) (Fukuda & Longnecker, 2005; Miller et al., 1994).
However, one caveat when using this system is that LMP2A
is expressed at very high levels and the cells are
immortalized, which is very different from resting, latently
infected B-cells in vivo (Caldwell et al., 2000; Thorley-
Lawson, 2001). Therefore, to assess the ability of LMP2A to
modulate BCR signalling and survival in resting B-cells,
our laboratory generated the LMP2A/HEL-Tg mouse
(Swanson-Mungerson et al., 2005). The advantage of using
transgenic (-Tg) HEL-Tg and LMP2A/HEL-Tg mice is that
the B-cells from these mice all express a BCR specific for
the antigen hen egg lysozyme (HEL). Therefore, we are able
to directly compare the ability of LMP2A to modulate BCR
signalling and B-cell survival when the only difference
between the two B-cells is the expression of LMP2A.
Previous studies using an LMP2A transgenic line that
expresses lower levels of LMP2A, the Tg6 line, indicate that
LMP2A alters BCR signalling after exposure to antigen-
independent BCR cross-linking (Portis & Longnecker,
2004a). To determine whether LMP2A alters BCR signalling
in response to antigen, we purified B-cells from HEL-Tg and
LMP2A/HEL-Tg mice and incubated these cells in the
absence or presence of antigen for up to 10 min. As shown
in Fig. 1(a), B-cells from both HEL-Tg and LMP2A/HEL-Tg
mice demonstrate a marked increase in tyrosine phosphor-
ylation after exposure to HEL or BCR cross-linking using a
polyclonal anti-Ig antibody. Interestingly, there are slight
differences in the banding pattern of some of the faster-
migrating phosphorylated proteins produced when com-
paring the HEL-Tg B-cells with the LMP2A/HEL-Tg B-cells Supplementary figures are available with the online version of this paper.
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that are differently modified are not known. Taken together,
these data indicate that LMP2A alters antigen-induced BCR
signalling in resting B-cells.
One downstream effect of BCR cross-linking is the
translocation of NF-kB into the nucleus (Schulze-
Luehrmann & Ghosh, 2006; Weil & Israel, 2004). Previous
studies by our laboratory indicated that LMP2A induces
constitutive NF-kB activation in B-cells generated from the
bone marrow (Swanson-Mungerson et al., 2005). To
determine whether LMP2A induces NF-kB nuclear local-
ization in splenic B-cells, we analysed nuclear lysates from
splenic B-cells from HEL-Tg and LMP2A/HEL-Tg mice
using an NF-kB transcription factor assay (Active Motif).
This assay quantifies the amount of nuclear NF-kB that
binds to an NF-kB consensus DNA oligonucleotide coating
on a 96-well plate (Swanson-Mungerson et al., 2005). As
shown in Fig. 1(b), LMP2A/HEL-Tg B-cells demonstrate
constitutive nuclear localization of NF-kB in the absence of
any external stimulus, which is in contrast to HEL-Tg B-
cells. These findings indicate that LMP2A continues to
activate NF-kB upon exit from the bone marrow and while
in the peripheral organs.
Since the data in Fig. 1(a) indicate that LMP2A alters BCR
signal transduction, we determined whether LMP2A also
influences the translocation of NF-kB after BCR cross-
linking by antigen. As shown in Fig. 1(b), HEL-Tg B-cells
exposed to antigen demonstrate a marked increase in NF-kB
levels compared with unstimulated HEL-Tg B-cells. The
amount of NF-kB induced by antigen in HEL-Tg B-cells is
equivalent to the levels of the constitutive NF-kB activation
in the unstimulated LMP2A/HEL-Tg B-cells (Fig. 1b). This
is interesting, since BCR cross-linking and NF-kB activation
in normal B-cells induce B-cells to enter the cell cycle (Doi
et al., 1997), yet LMP2A/HEL-Tg B-cells do not proliferate
unless they are stimulated with antigen and/or mitogen (M.
Swanson-Mungerson & R. Longnecker, unpublished obser-
vation). Therefore, these data suggest that LMP2A-induced
Fig. 1. LMP2A influences BCR signalling and
Bcl family member expression. (a) B-cells from
HEL-Tg and LMP2A/HEL-Tg mice were puri-
fied to .95% purity as previously described
(Swanson-Mungerson et al., 2006). B-cells
(110
6) were incubated in the absence or
presence of HEL (1 mgm l
”1) or goat anti-
mouse Ig (10 mgm l
”1) for up to 10 min before
protein was isolated and analysed for tyrosine
phosphorylation using Western blot analysis
as described previously (Portis & Longnecker,
2004a). The data are representative of two
independent experiments with similar results.
(b) HEL-Tg and LMP2A/HEL-Tg purified B-
cells were incubated as described in Fig. 1(a)
with HEL [1 mgm l
”1, HEL (1); or 10 mgm l
”1,
HEL (10)] and analysed for nuclear localization
of the p65 subunit of NF-kB as described
previously (Swanson-Mungerson et al., 2005).
The data are representative of three experi-
ments with similar results. (c, d) HEL-Tg and
LMP2A/HEL-Tg B-cells were isolated and
immediately fixed with Cytofix/Cytoperm (BD
Biosciences) according to the manufacturer’s
protocol. The cells were subsequently stained
with either Alexa Fluor 488-conjugated anti-
Bcl-xL or phycoerythrin-conjugated anti-Bcl-2
and analysed by flow cytometry. The data were
subsequently analysed using FlowJo software
and are representative of at least three mice.
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Therefore, it is likely that constitutively high levels of
LMP2A-induced NF-kB provide a pro-survival function in
the absence of BCR cross-linking, rather than a pro-
activation signal. When LMP2A/HEL-Tg B-cells are stimu-
lated with antigen, the levels of NF-kB nuclear localization
are further increased, suggesting that LMP2A enhances
BCR-induced NF-kB activation (Fig. 1b). Interestingly,
when anti-Ig antibody cross-links the BCR as a positive
control for NF-kB nuclear localization, LMP2A does not
markedly increase NF-kB localization (Fig. 1b), which
suggests that the stimulus used when studying the function
of LMP2A on BCR cross-linking is important. Taken
together, these data demonstrate that LMP2A induces
constitutive NF-kB activation and further augments BCR-
induced NF-kB nuclear localization after antigen exposure.
Previous data indicate that LMP2A increases the levels of
NF-kB-regulated anti-apoptotic proteins, such as Bcl-2 and
Bcl-xL, in the absence of a BCR (Portis & Longnecker,
2004b). Since LMP2A consistently activates NF-kB, we
determined whether LMP2A also increases expression of
these proteins in a B-cell that expresses a BCR. Using flow
cytometric analysis, both LMP2A/HEL-Tg and HEL-Tg
B-cells express very low levels of Bcl-xL (Fig. 1c). This is
not surprising in the HEL-Tg B-cells, since previous data
demonstrate that Bcl-xL expression is more predominant
during B-cell development than in resting B-cells found in
the spleen (Grillot et al., 1996). In contrast, the absence of
Bcl-xL expression is surprising in the LMP2A/HEL-Tg B-
cells, because B-cells from TgE mice express high levels of
Bcl-xL [(Portis & Longnecker, 2004b) and flow cytometric
data (Supplementary Fig. S1, available in JGV Online)].
Due to the fact that B-cells from LMP2A-Tg (TgE) mice do
not express a BCR (Caldwell et al., 1998), it is possible that
TgE B-cells are more similar to developing B-cells, which
express Bcl-xL, than mature B-cells found in the spleen.
Therefore, we propose that the forced expression of a BCR
in the LMP2A/HEL-Tg B-cells yields mature B-cells and a
return to the normal regulation of anti-apoptotic genes.
Bcl-2 is constitutively expressed at low levels in mature B-
cells, presumably to maintain survival in the absence of B-
cell activation (Grossmann et al., 2000). Based on previous
data (Portis & Longnecker, 2004b) and our observations,
we expected to see Bcl-2 in the BCR-expressing B-cells of
the HEL-Tg and LMP2A/HEL-Tg B mice. While both
express Bcl-2, LMP2A/HEL-Tg B-cells express more Bcl-2,
Fig. 2. NF-kB inhibitionaffectsBcl-2 levels and
apoptosis in unstimulated LMP2A/HEL-Tg B-
cells. (a, b) HEL-Tg and LMP2A/HEL-Tg B-cells
were incubated for 4 h in the presence of either
DMSO (unstimulated) or 5 mgm l
”1 of the NF-
kB inhibitor Bay 11-7085 (unstimulated+Bay).
At the end ofthis incubation, cells werefixedand
stained as described for Fig. 1(c, d). The data
represent the fold increase in the percentage of
Bcl-expressing B-cells and were derived by
combining the data from three or four mice.
*Indicating P,0.05 by unpaired Student’s t-test
when compared with DMSO-exposed HEL-Tg
B-cells. **Indicating P,0.05 by unpaired
Student’s t-test when compared with DMSO-
exposed LMP2A/HEL-Tg B-cells. (c, d) HEL-Tg
and LMP2A/HEL-Tg B-cells were incubated for
18 h in the presence of either DMSO (unstimu-
lated) or Bay 11-7085 (unstimulated+Bay). The
B-cells were subsequently fixed and stained for
the presence of DNA double-stranded breaks
using an ApoDirect kit (BD Biosciences) as
described previously (Portis & Longnecker,
2004b). Additional NF-kB inhibitors (PDTC
and SN50) were used and generated similar
results (unpublished data). After flow cytometry,
the data were analysed using Diva software. The
data are representative of three or four mice with
similar results.
LMP2A protects B-cells from apoptosis via NF-kB and Bcl
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comparing the histogram of the LMP2A/HEL-Tg cells
with HEL-Tg B-cells (Fig. 1d; thick line, LMP2A/HEL-Tg;
thin line, HEL-Tg). We subsequently measured whether
LMP2A-mediated increases in Bcl-2 require the activation
of NF-kB. The addition of an NF-kB inhibitor (Bay 11-
7085) blocks the LMP2A-mediated increase in Bcl-2 in
LMP2A/HEL-Tg B-cells (Fig. 2a). However, the NF-kB
inhibitor does not significantly affect the levels of Bcl-2-
positive HEL-Tg B-cells (Fig. 2a). Furthermore, the
addition of the NF-kB inhibitor had no significant effect
on Bcl-xL levels in either resting HEL-Tg or LMP2A/HEL-
Tg B-cells (Fig. 2b). Taken together, these data suggest that
LMP2A increases NF-kB activation to selectively increase
Bcl-2 in resting, mature B-cells.
Previous studies indicate that LMP2A protects B-cells from
apoptosis (Fukuda & Longnecker, 2005; Mancao &
Hammerschmidt, 2007; Portis & Longnecker, 2004b). To
determine whether LMP2A protects B-cells from apoptosis
in our transgenic mouse model, we analysed the percentage
of apoptotic cells by using an ApoDirect kit from BD
Biosciences. This assay fluorescently tags double-stranded
DNA breaks, thus allowing the analysis of the percentage of
cells that are in the irreversible stages of apoptosis by flow
cytometry (Portis & Longnecker, 2004b). LMP2A/HEL-Tg
B-cells have significantly fewer apoptotic cells (54%) than
HEL-Tg B-cells (65%), further supporting the role of
LMP2A in protecting cells from apoptosis [Fig. 2c(i), (iii)].
Similar experiments using Annexin V staining also dem-
onstrate that LMP2A protects B-cells from apoptosis
(Supplementary Fig. S2, available in JGV Online). We
determined that the increases in NF-kB and Bcl-2 are
important to protect unstimulated LMP2A/HEL-Tg B-cells
from apoptosis by incubating purified HEL-Tg and LMP2A/
HEL-Tg B-cells in the absence or presence of the NF-kB
inhibitor. The addition of the NF-kB inhibitor significantly
increases the percentage of apoptotic LMP2A/HEL-Tg B-
cells [Fig. 2c(i)–(iv)], as determined by the shift of the
population from being negative to positive for double-
stranded DNA breaks [LMP2A/HEL-Tg+Bay (80% pos-
itive) versus LMP2A/HEL-Tg+DMSO (54% positive)],
while the NF-kB inhibitor has little effect on the HEL-Tg
B-cells [(HEL-Tg+Bay (64% positive) versus LMP2A/HEL-
Tg+DMSO (65% positive)][ Fig. 2c(i), (ii)]. These data
indicate that resting LMP2A-expressing B-cells are uniquely
sensitive to NF-kB inhibition. Since inhibition of NF-kB
results in reduced expression of Bcl-2 and not Bcl-xL in
Fig. 3. NF-kB inhibition affects levels of Bcl
family members and apoptosis in both LMP2A/
HEL-Tg and HEL-Tg B-cells after antigen
exposure. (a, b) HEL-Tg and LMP2A/HEL-Tg
B-cells were incubated as described above (Fig.
2a, b) and in the presence of HEL (1 mgm l
”1).
The data represent the fold increase in the
percentage of Bcl-expressing B-cells compared
with resting, non-antigen-exposed HEL-Tg B-
cells and are a combination of three or four mice.
*Indicating P,0.05 by unpaired Student’s t-test
when compared with DMSO-exposed HEL-Tg
B-cells. **Indicating P,0.05 by unpaired
Student’s t-test when compared with DMSO-
exposed LMP2A/HEL-Tg B-cells. (c) HEL-Tg
and LMP2A/HEL-Tg B-cells were incubated for
18 h as describedabovefor Fig. 2(c) using1 mg
HEL ml
”1. The B-cells were analysed as
described above for Fig. 2(c). The data are
representative of three or four mice with similar
results.
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not Bcl-xL, mediates the enhanced survival of LMP2A/HEL-
Tg B-cells when compared to HEL-Tg B-cells (Fig. 2c).
Stimulation through the BCR is known to increase NF-kB
activation with subsequent activation of Bcl-2 and Bcl-xL
to promote cell survival (Gugasyan et al., 2000). HEL-Tg B-
cells exposed to antigen show significantly increased Bcl-2
and Bcl-xL levels, which is reversed by the addition of the
NF-kB inhibitor (Figs 3a, b). Since these B-cells now
express higher levels of Bcl family members, we determined
whether exposure of HEL-Tg B-cells to antigen now made
the survival of these cells NF-kB-dependent. Antigen-
exposed HEL-Tg B-cells demonstrate an increase in
apoptosis when exposed to an NF-kB inhibitor [Ag: 78%
versus Ag+Bay: 90%; Fig. 3c(i), (ii)], suggesting that, in
contrast to resting B-cells, antigen-activated B-cells are
dependent on NF-kB signalling for survival.
We determined whether antigen-activated LMP2A/HEL-Tg
B-cells also require NF-kB-dependent increases in Bcl-2
and Bcl-xL levels for survival. As shown in Fig. 3(a),
antigen-activated LMP2A/HEL-Tg B-cells increase Bcl-2
levels that are then reversed by the addition of the NF-kB
inhibitor. Additionally, the antigen-induced increase in Bcl-
xL levelsin LMP2A/HEL-Tg B-cellsis reversedby the NF-kB
inhibitor (Fig. 3b). Consequently, when these cells are
analysed for levels of apoptosis, antigen-activated LMP2A/
HEL-Tg B-cells demonstrate an increased level of apoptosis
in the presence of the NF-kB inhibitor [Ag: 59% versus
Ag+Bay: 80%; Fig. 3c(iii), (iv)]. Taken together, these data
demonstrate that LMP2A requires NF-kB signalling, and
probably also the subsequent activation of Bcl-2 and/or Bcl-
xL for survival in the presence of BCR-cross-linking.
The data presented here identify a surprising and unique
dependence of LMP2A-expressing B-cells for NF-kB activa-
tion. In comparison with previously published findings, the
data presented here indicate that the mechanisms by which
LMP2A protects non-transformed B-cells from apoptosis
may be slightly different from the mechanisms employed by
LMP2A in cell lines. In cell lines, LMP2A blocks the
induction of apoptosis by blocking BCR signalling (Fukuda
& Longnecker, 2005). However, in non-transformed cells
LMP2A may constitutively activate NF-kB and Bcl-2 to
protect cells from apoptosis.
The idea that LMP2A blocks BCR signalling to inhibit the
induction of the lytic cycle provides a model for the role of
LMP2A inthemaintenance oflatency (Longnecker & Miller,
1996). However, more recent evidence indicates that the
maintenance of latency and regulation of EBV latency genes
aremuch more complex. Latencygenes and the genes forthe
inductionofthelyticcyclecanberegulatedbycytokines(Kis
et al., 2006, 2010; Konforte & Paige, 2009; Konforte et al.,
2008; Uchakin et al., 2007), other viral proteins and
microRNAs (Dawson et al., 2001; Guasparri et al., 2008;
Lung et al., 2009; Stewart et al., 2004) and autoregulation
(Anderson & Longnecker, 2008). Therefore, it is likely that
many different environmental factors, not just antigens, are
important in the regulation of EBV latent infection and the
switch to lytic virus replication.
Our data suggest that LMP2A requires NF-kB for the
transcription and production of Bcl family members to
promote survival. We think that it would be interesting to
determine whether LMP2A uses Bcl-2 exclusively in both
resting and activated B-cells to protect B-cells from
apoptosis. There is evidence that LMP2A may use different
Bcl family members under different conditions in vivo,
since LMP2A only upregulates Bcl-xL in the presence of
Myc overexpression (Bultema et al., 2009). However, it is
conceivable that the environment in which the latently
infected B-cells reside will dictate the usage and/or skewing
in favour of using one anti-apoptotic protein or another.
Taken together, these data provide results indicating that
LMP2A makes unstimulated B-cells uniquely sensitive to
NF-kB inhibition. This provides the basis for the therapeutic
targeting of resting, latently infected B-cells expressing
LMP2A for eradication of EBV prior to the development of
EBV-associated lymphomas.
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